Validation of the Cholinergic Urticaria Activity Score (CholUAS).

IF 8.2 1区医学 Q1 ALLERGY Journal of Allergy and Clinical Immunology-In Practice Pub Date : 2024-10-16 DOI:10.1016/j.jaip.2024.10.011

Pia Schnarkowski, Pascale Salameh, Eva Grekowitz, Dorothea Terhorst-Molawi, Marcus Maurer, Karsten Weller, Sabine Altrichter

{"title":"Validation of the Cholinergic Urticaria Activity Score (CholUAS).","authors":"Pia Schnarkowski, Pascale Salameh, Eva Grekowitz, Dorothea Terhorst-Molawi, Marcus Maurer, Karsten Weller, Sabine Altrichter","doi":"10.1016/j.jaip.2024.10.011","DOIUrl":null,"url":null,"abstract":"Background: In cholinergic urticaria (CholU), itchy wheal and flare-type skin reactions are triggered by sweat-inducing activities. The CholU activity score (CholUAS) is used to assess disease activity but has not yet been validated. The aim of the study was to validate the CholUAS, develop an English version, and provide instructions for scoring.Methods: Cognitive debriefing of CholUAS was performed. Patients with CholU (n = 75) used the CholUAS on 7 consecutive days, underwent provocation testing, completed additional anchor instrument questionnaires including global evaluation tools, and established quality of life instruments. A scoring protocol for the calculation of the weekly CholUAS, the CholUAS7, was developed. The CholUAS7 was tested for validity, reliability, and influencing factors. An English version of the CholUAS was developed.Results: The final CholUAS contains 3 questions that are used for scoring as well as 1 global question. The weekly CholUAS, CholUAS7, showed excellent test-retest reliability and good correlations with anchor instruments. Statistical analysis showed no significant influence of age or duration of disease on CholUAS7 results.Conclusion: The validated CholUAS is ready for use in clinical trials and routine clinical practice.","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaip.2024.10.011","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In cholinergic urticaria (CholU), itchy wheal and flare-type skin reactions are triggered by sweat-inducing activities. The CholU activity score (CholUAS) is used to assess disease activity but has not yet been validated. The aim of the study was to validate the CholUAS, develop an English version, and provide instructions for scoring.

Methods: Cognitive debriefing of CholUAS was performed. Patients with CholU (n = 75) used the CholUAS on 7 consecutive days, underwent provocation testing, completed additional anchor instrument questionnaires including global evaluation tools, and established quality of life instruments. A scoring protocol for the calculation of the weekly CholUAS, the CholUAS7, was developed. The CholUAS7 was tested for validity, reliability, and influencing factors. An English version of the CholUAS was developed.

Results: The final CholUAS contains 3 questions that are used for scoring as well as 1 global question. The weekly CholUAS, CholUAS7, showed excellent test-retest reliability and good correlations with anchor instruments. Statistical analysis showed no significant influence of age or duration of disease on CholUAS7 results.

Conclusion: The validated CholUAS is ready for use in clinical trials and routine clinical practice.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胆碱能性荨麻疹活动评分 CholUAS 的验证。

背景：在胆碱能性荨麻疹（CholU）中，出汗活动会引发瘙痒性麦粒肿和发作型皮肤反应。胆碱能性荨麻疹活动评分（CholUAS）用于评估疾病活动，但尚未得到验证。本研究旨在验证 CholUAS，开发英文版本，并提供评分说明：方法：对 CholUAS 进行认知汇报。胆汁淤积症患者（n = 75）连续 7 天使用胆汁淤积症评估系统，接受激惹试验，并完成其他锚定工具问卷，包括全球评估工具和既定的生活质量工具。为计算每周 CholUAS（即 CholUAS7）制定了评分标准。对 CholUAS7 的有效性、可靠性和影响因素进行了测试。同时还开发了英文版的 CholUAS：最终的 CholUAS 包括 3 个用于评分的问题和一个综合问题。每周一次的 CholUAS，即 CholUAS7，显示出极佳的测试再测可靠性，并与锚定工具有良好的相关性。统计分析显示，年龄或病程对 CholUAS7 的结果没有明显影响：经过验证的胆固醇测量系统可用于临床试验和常规临床实践。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Allergy and Clinical Immunology-In Practice ALLERGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

11.10

自引率

9.60%

发文量

683

审稿时长

50 days

期刊介绍： JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases. This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders. The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.